𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recruitment to a clinical trial from the databases of specialists in Parkinson's disease

✍ Scribed by Ann Ashburn; M. Pickering Ruth; Fazakarley Louise; Ballinger Claire; McLellan D. Lindsay; Fitton Carolyn

Book ID
116820233
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
115 KB
Volume
13
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Test–Retest reliability of the Unified P
Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial
✍ Andrew Siderowf; Michael McDermott; Karl Kieburtz; Karen Blindauer; Sandra Plumb πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 1 views

Our objective was to assess the test-retest reliability of the Unified Parkinson's Disease Rating Scale (UPDRS). The UPDRS is the most widely used instrument for measuring severity of parkinsonian symptoms in clinical research and in practice. The validity and inter-rater reliability of this scale h

A recommended scale for cognitive screen
A recommended scale for cognitive screening in clinical trials of Parkinson's disease
✍ Kelvin L. Chou; Melissa M. Amick; Jason Brandt; Richard Camicioli; Karen Frei; D πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 1 views

## Abstract Cognitive impairment is common in Parkinson's disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition. The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task Force to

Interpreting the results of Parkinson's
Interpreting the results of Parkinson's disease clinical trials: Time for a change
✍ Nick H. G. Holford; John G. Nutt πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 199 KB πŸ‘ 1 views

## Abstract Randomized clinical trials testing putative disease‐modifying agents in Parkinson's disease (PD) have yielded controversial results that have not influenced evidence‐based recommendations for the treatment of PD. We argue that the failure of these clinical trials may be linked to end po